시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 중간엽 줄기세포 시장 분석과 예측(-2034년) : 유형, 제품, 서비스, 기술, 용도, 최종 사용자, 프로세스, 기능성
Mesenchymal Stem Cells Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Process, Functionality
상품코드 : 1699146
리서치사 : Global Insight Services LLC
발행일 : 2025년 04월
페이지 정보 : 영문 482 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,603,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 7,994,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,384,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 중간엽 줄기세포 시장은 2024년 34억 달러에서 2034년까지 113억 달러로 확대되어, 약 12.8%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측되고 있습니다. MSC는 성형외과, 심장혈관, 자가면역질환 등 다양한 질환의 치료에 매우 중요합니다. 세포 배양기술의 진보, 임상시험 증가, 재생의료에 대한 투자 증가가 시장을 견인하고 있습니다.

시장 개요:

중간엽 줄기세포(MSCs) 시장은 다양한 용도와 큰 성장의 가능성을 특징으로 하고 있습니다. 유병률 증가, 세포 기반 치료법의 진보, 심혈관 질환, 정형외과 질환, 자가면역 질환 등의 다양한 병리의 치료에 있어서의 MSC의 수용의 확대에 기인하고 있습니다. 화장품에 대한 응용이나 맞춤형 의료에 MSCs와 같은 새로운 하위 부문이 견인력을 늘리고 있어 시장 확대의 유망한 길을 제공합니다. 용시술에 대한 소비자 수요가 높아짐에 따라 관심이 높아지고 있습니다. 맞춤형 치료 접근법에 MSC를 활용하는 맞춤형 의료는 변혁의 가능성을 갖고 있으며, 환자 고유의 치료법에 혁명을 가져와 시장 성장을 더욱 촉진할 것으로 기대되고 있습니다.

시장 세분화
유형 자가, 동종, 이종
제품 세포주, 배양액, 시약 및 키트
서비스 셀 뱅킹, 세포 특성 분석, 세포 분화
기술 세포 증식, 세포 분리, 동결보존
용도 재생 의료, 창약, 조직 공학, 정형외과, 심장혈관, 신경학, 종양학
최종 사용자 바이오 제약 회사, 조사 기관, 병원, 클리닉
프로세스 시험관내, 생체내
기능성 다능성, 만능성

중간엽 줄기세포 시장은 다양한 세분화에 의해 특징지어지며, 재생의료와 세포치료 수요 증가에 견인되어, 치료용도 부문이 큰 점유율을 차지하고 있습니다. 북미가 강력한 헬스케어 인프라와 연구 이니셔티브에 힘입어 압도적인 힘을 유지하고 있는 한편, 아시아태평양은 헬스케어와 생명공학 분야에 대한 투자 증가로 가속적인 성장을 이루고 있습니다. 특히 북미와 유럽에서는 줄기세포 치료의 안전성과 유효성을 확보하기 위해 엄격한 가이드라인이 정해져 있어 규제 당국의 영향은 시장의 역학을 형성하는데 있어 매우 중요합니다. 중요합니다. 시장 전망은 낙관적이며 기술적 진보와 임상 응용 증가로 지속적인 성장이 예상되고 있습니다.

주요 동향과 촉진요인:

중간엽 줄기세포(MSC) 시장은 재생의료와 세포치료의 진보에 힘입어 강력한 성장을 이루고 있습니다. 향후 치료를 대체할 수 있는 유망한 선택을 제공하고 있으며, 만성질환의 세계 유병률 상승은 혁신적인 치료법에 대한 수요를 촉진하고 MSC를 헬스케어에서 중요한 요소로 자리매김하고 있습니다. 이것은 임상시험이나 승인을 가속시키는 유리한 규제적 틀과 연관되어 있습니다. 증가함에 따라 시장은 크게 확대되고 있으며, 확장 가능한 생산 기술과 비용 효율적인 솔루션에 중점을 둔 기업은 이러한 새로운 비즈니스 기회를 활용할 수있는 좋은 위치에 놓여 있습니다.

억제와 도전:

중간엽 줄기세포 시장에는 몇 가지 현저한 억제요인과 도전이 있습니다. 중요한 장애물은 규제 상황의 엄격함으로, 이는 새로운 치료법의 승인 획득을 복잡하게 하고 시장 출시까지의 시간을 늘리고 있습니다. 높은 생산 비용은 이 문제를 더욱 악화시키고 중소기업 경쟁과 기술 혁신을 어렵게 만듭니다. 또한 제조 공정이 표준화되어 있지 않기 때문에 제품의 품질과 유효성에 편차가 발생하고 있습니다. 장기적인 안전과 효능에 대한 임상 데이터와 증거가 제한되어 있어 건강관리자들 사이에서 널리 채택되고 받아들이는 것을 방해하고 있습니다. 게다가 줄기세포 연구를 둘러싼 윤리적인 우려는 사회적인 논의를 계속해서 일으키고 있으며, 규제 당국의 결정과 자금 조달에 영향을 미칠 수 있습니다. 이러한 과제는 일반적으로 중간엽 줄기세포 시장의 성장과 발전에 큰 장벽이 되고 있습니다.

목차

제1장 중간엽 줄기세포 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 중간엽 줄기세포 시장 전망

제5장 중간엽 줄기세포 시장 전략

제6장 중간엽 줄기세포 시장 규모

제7장 중간엽 줄기세포 시장 : 유형별

제8장 중간엽 줄기세포 시장 : 제품별

제9장 중간엽 줄기세포 시장 : 서비스별

제10장 중간엽 줄기세포 시장 : 기술별

제11장 중간엽 줄기세포 시장 : 용도별

제12장 중간엽 줄기세포 시장 : 최종 사용자별

제13장 중간엽 줄기세포 시장 : 프로세스별

제14장 중간엽 줄기세포 시장 : 기능별

제15장 중간엽 줄기세포 시장 : 지역별

제16장 경쟁 구도

제17장 기업 프로파일

JHS
영문 목차

영문목차

Mesenchymal Stem Cells Market is anticipated to expand from $3.4 billion in 2024 to $11.3 billion by 2034, growing at a CAGR of approximately 12.8%. The market encompasses the development, application, and commercialization of MSC-based therapies, known for their regenerative and immunomodulatory properties. MSCs are pivotal in treating various conditions, including orthopedic, cardiovascular, and autoimmune disorders. The market is driven by advancements in cell culture technologies, increasing clinical trials, and rising investments in regenerative medicine. Regulatory support and emerging applications in personalized medicine further propel growth, highlighting the potential of MSCs in transforming therapeutic landscapes.

Market Overview:

The Mesenchymal Stem Cells (MSCs) Market is characterized by its diverse applications and significant growth potential. The therapeutics segment emerges as the leading market segment, driven by the rising demand for regenerative medicine and advanced therapeutic solutions. This segment's dominance is attributed to the increasing prevalence of chronic diseases, advancements in cell-based therapies, and the growing acceptance of MSCs in treating various medical conditions, including cardiovascular, orthopedic, and autoimmune disorders. Technological advancements in cell culture techniques and enhanced understanding of stem cell biology further bolster this segment's leadership. Emerging sub-segments such as MSCs for cosmetic applications and personalized medicine are gaining traction, offering promising avenues for market expansion. The cosmetic application of MSCs, particularly in anti-aging treatments and skin regeneration, is witnessing increased interest due to the rising consumer demand for non-invasive aesthetic procedures. Personalized medicine, leveraging MSCs for tailored therapeutic approaches, holds transformative potential, promising to revolutionize patient-specific treatment modalities and further drive market growth.

Market Segmentation
TypeAutologous, Allogeneic, Xenogeneic
ProductCell Lines, Culture Media, Reagents and Kits
ServicesCell Banking, Cell Characterization, Cell Differentiation
TechnologyCell Expansion, Cell Isolation, Cryopreservation
ApplicationRegenerative Medicine, Drug Discovery, Tissue Engineering, Orthopedic, Cardiovascular, Neurology, Oncology
End UserBiopharmaceutical Companies, Research Institutes, Hospitals and Clinics
ProcessIn Vitro, In Vivo
FunctionalityMultipotent, Pluripotent

The Mesenchymal Stem Cells market is characterized by a diverse segmentation where the therapeutic applications segment holds a significant share, driven by the increasing demand for regenerative medicine and cell therapy. The research applications segment also commands attention due to ongoing advancements in stem cell research and biotechnology. Geographically, North America remains a dominant force, propelled by robust healthcare infrastructure and research initiatives, while the Asia-Pacific region is witnessing accelerated growth owing to rising investments in healthcare and biotechnology sectors. The competitive landscape is marked by the presence of key players such as Lonza Group, Thermo Fisher Scientific, and STEMCELL Technologies, who are actively engaged in strategic collaborations and innovations to enhance their market positions. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent guidelines ensuring the safety and efficacy of stem cell therapies. The market outlook is optimistic, with projections indicating sustained growth driven by technological advancements and increasing clinical applications. However, challenges such as ethical concerns and regulatory complexities persist, yet the potential for breakthroughs in personalized medicine and tissue engineering presents lucrative opportunities for market expansion.

Geographical Overview:

The Mesenchymal Stem Cells (MSC) market is witnessing varied growth patterns across different regions. North America remains at the forefront, driven by advanced healthcare infrastructure and substantial investments in regenerative medicine. The region's strong focus on research and development further propels market growth. In Europe, the MSC market is growing steadily. This growth is supported by increasing clinical trials and a robust regulatory framework fostering innovation. The region's emphasis on personalized medicine enhances its market potential. In the Asia Pacific, the MSC market is expanding rapidly. This growth is fueled by rising healthcare expenditures and a growing interest in stem cell research. Countries like China and Japan are investing heavily in stem cell therapies, contributing to the region's robust market dynamics. Latin America is an emerging market with increasing potential. The region is witnessing a surge in healthcare investments and growing awareness about stem cell therapies. The Middle East & Africa region is recognizing the importance of MSCs in advancing healthcare outcomes. Governments are investing in healthcare infrastructure, and there is a growing interest in regenerative medicine. This is paving the way for future market growth. Overall, each region presents unique opportunities and challenges, making the global MSC market a dynamic and promising landscape for stakeholders.

Recent Development:

The Mesenchymal Stem Cells (MSCs) market has witnessed several noteworthy developments in recent months. Lonza Group announced a strategic partnership with a leading biotech firm to enhance its MSC production capabilities, focusing on scaling up manufacturing processes for therapeutic applications. Meanwhile, Thermo Fisher Scientific has unveiled an innovative MSC product line, designed to improve cell viability and potency, which is expected to bolster their market position. In regulatory news, the FDA has issued new guidelines to streamline the approval process for MSC-based therapies, aiming to accelerate the delivery of safe and effective treatments to patients. Additionally, a joint venture between two prominent pharmaceutical companies is set to advance MSC research, with a focus on developing novel therapies for degenerative diseases. Lastly, a recent market analysis revealed an increasing investment trend in the MSC sector, driven by the rising demand for regenerative medicine solutions and the promising therapeutic potential of MSCs in various clinical applications.

Key Trends and Drivers:

The Mesenchymal Stem Cells (MSC) market is experiencing robust growth, propelled by advancements in regenerative medicine and cell therapy. Key trends include the increasing integration of MSCs in treating chronic diseases, such as cardiovascular and autoimmune disorders. This surge is driven by the cells' unique ability to differentiate and repair damaged tissues, offering a promising alternative to traditional treatments. Furthermore, the rising prevalence of chronic diseases globally is fostering demand for innovative therapies, positioning MSCs as a crucial component in the healthcare landscape. The market is also witnessing heightened investment in research and development, with companies striving to enhance the efficacy and safety of MSC-based therapies. This is coupled with favorable regulatory frameworks that are accelerating clinical trials and approvals. Additionally, the expansion of MSC applications beyond traditional healthcare into areas like cosmetic and anti-aging treatments presents lucrative opportunities. As consumer awareness regarding the benefits of stem cell therapies grows, the market is poised for significant expansion. Companies focusing on scalable production techniques and cost-effective solutions are well-positioned to capitalize on these emerging opportunities. The MSC market stands at the forefront of a transformative era in medical science, promising both innovation and growth.

Restraints and Challenges:

The mesenchymal stem cells market encounters several prominent restraints and challenges. A significant hurdle is the stringent regulatory landscape, which complicates approvals and prolongs time-to-market for new therapies. High production costs further exacerbate this issue, making it difficult for smaller companies to compete and innovate. Additionally, there is a lack of standardization in manufacturing processes, leading to variability in product quality and efficacy. Limited clinical data and evidence on long-term safety and effectiveness also hinder widespread adoption and acceptance among healthcare professionals. Furthermore, ethical concerns surrounding stem cell research continue to spark public debate and may influence regulatory decisions and funding. These challenges collectively pose significant barriers to the growth and advancement of the mesenchymal stem cells market.

Key Companies:

Cynata Therapeutics, Mesoblast, Athersys, Pluristem Therapeutics, Celltex Therapeutics, Stempeutics Research, Bio Cardia, Anterogen, Osiris Therapeutics, Brain Storm Cell Therapeutics, Promethera Biosciences, Re Neuron Group, Cellect Biotechnology, Steminent Biotherapeutics, Orbsen Therapeutics, Stemedica Cell Technologies, Cytori Therapeutics, Medipost, Thermo Genesis Holdings, American Cryo Stem

Sources:

National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), International Society for Stem Cell Research (ISSCR), International Society for Cellular Therapy (ISCT), Stem Cell Network, European Society of Gene and Cell Therapy (ESGCT), Harvard Stem Cell Institute, Stanford University School of Medicine, Mayo Clinic Center for Regenerative Medicine, University of California, San Francisco (UCSF) Stem Cell Center, Centre for Commercialization of Regenerative Medicine (CCRM), Japan Agency for Medical Research and Development (AMED), Regenerative Medicine Foundation, National Stem Cell Foundation, California Institute for Regenerative Medicine (CIRM), International Conference on Stem Cell and Regenerative Medicine, World Stem Cell Summit, Mesenchymal Stem Cell Conference

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Mesenchymal Stem Cells Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Mesenchymal Stem Cells Market Outlook

5: Mesenchymal Stem Cells Mesenchymal Stem Cells Market Strategy

6: Mesenchymal Stem Cells Market Size

7: Mesenchymal Stem Cells Market, by Type

8: Mesenchymal Stem Cells Market, by Product

9: Mesenchymal Stem Cells Market, by Services

10: Mesenchymal Stem Cells Market, by Technology

11: Mesenchymal Stem Cells Market, by Application

12: Mesenchymal Stem Cells Market, by End User

13: Mesenchymal Stem Cells Market, by Process

14: Mesenchymal Stem Cells Market, by Functionality

15: Mesenchymal Stem Cells Market, by Region

16: Competitive Landscape

17: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기